MedTech Dive February 9, 2022
Dive Brief:
- Moody’s Investors Service has called out healthcare staffing shortages and supply chain disruptions as two factors that could continue to affect medical device companies into 2022. While shortages of components and elevated shipping costs are expected to be “manageable,” hospital capacity constraints could impact procedure-dependent medtechs, according to the Jan. 31 quarterly report.
- Demand for COVID-19 testing has remained elevated for longer than expected, but it’s not anticipated to continue at current levels. Still, Moody’s expects that rapid at-home tests could provide ongoing revenue for some diagnostics companies, even if at lower levels in the future.
- Medtech companies are expecting another busy year for mergers and acquisitions, though Moody’s is forecasting fewer “mega deals.” In their most...
Today's Sponsors
Today's Sponsor